ClinicalTrials.gg
TerminatedNCT02521870Updated Aug 3, 2021Results posted

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Phase 1/2 interventional study of SD-101(1) and Pembrolizumab in Metastatic Melanoma and Head Neck Cancer, sponsored by Dynavax Technologies Corporation. Terminated at 47 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-03.

Sponsored by Dynavax Technologies Corporation (part of Sanofi) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
A strategic restructuring including the planned conclusion of clinical oncology development programs and no further sponsoring of the development of SD-101.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
241
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,049 studies in Melanoma with a site in United States — 243 open to participants now, 440 under way, 32 of them phase 3. Melanoma · United States.

Enrollment
201st of 1,749
241 · median 37
Started
2015
with 107 others
Phase 1/2
287 of 2,049
51 open now
Registered
1,121st of 2,049
by date

Among the 2,049 studies in Melanoma with a site in United States, this one is the 201st largest by enrollment of the 1,749 interventional ones that give a count, is one of 108 that started in 2015, is one of 287 in phase 1/2, and was the 1,121st registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

243 of the 2,049 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

238 more — sign in →

All 243 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,049 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

This is a phase 1b/2, open-label, multicenter trial designed to evaluate the safety, tolerability, biologic activity, and preliminary efficacy of intratumoral SD-101 injections in combination with intravenous pembrolizumab in patients with metastatic melanoma or recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

This study will be conducted in 2 phases. Phase 1 evaluates SD-101 given in combination with pembrolizumab in melanoma populations (anti-PD-1/L1 naïve and anti-PD-1/L1 experienced with progressive disease) in up to 4 Dose Escalation cohorts to identify a recommended Phase 2 dose (RP2D) to be evaluated in up to 4 Dose Expansion cohorts in Phase 2. Phase 2 also includes up to 4 Dose Expansion cohorts of patients with HNSCC (anti-PD-1/L1 naïve and anti-PD-1/L1 experienced with progressive disease).

03

Conditions studied

  • Metastatic Melanoma
  • Head Neck Cancer

Keywords

  • Skin Cancer
  • Skin Tumors
  • Head and Neck Squamous Cell Carcinoma
  • Cancer Immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

[Inclusion Criteria (Phase 1 and Phase 2)]

  1. Willing and able to provide written for the trial
  2. Aged 18 years and older
  3. (ECOG) Performance Status (PS) of 0 or 1
  4. Patient must have adequate organ function as indicated by the following laboratory values:

    1. Hematological:

      • (ANC) ≥ 1,500 /mcL
      • count ≥ 100,000 /mcL
      • ≥ 9 g/dL or ≥ 5.6 mmol/L
    2. Renal:

      • Serum creatinine ≤ 1.5 × (ULN) OR
      • Measured or calculated ( can also be used in place of creatinine or CrCl) ≥ 60 mL/min for subject with creatinine levels > 1.5 × institutional ULN
    3. Hepatic:

      • Serum total :
      • ≤ 1.5 × ULN OR
      • \< 3 × ULN for persons with Gilbert's syndrome OR
      • Direct bilirubin ≤ ULN for patients with total bilirubin levels > 1.5 × ULN
      • (AST) and alanine transaminase (ALT) (also known as serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase)
      • ≤ 2.5 × ULN OR
      • ≤ 5 × ULN for patients with liver
    4. Coagulation:

      • or prothrombin time (PT) ≤ 1.5 × ULN unless patient is receiving anticoagulant therapy, and as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants
      • Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN unless patient is receiving anticoagulant therapy, and as long as PT or PTT is within therapeutic range of intended use of anticoagulants
  5. Have provided 2 tissue samples taken of the target lesion (Lesion A) as a single biopsy split into 2 samples or 2 separate biopsies that meet the minimal sample size requirement per the study laboratory manual. One sample is for determining expression level by immunohistochemistry and can be an archival sample of the anticipated target lesion that has been collected within 3 months of screening. The other sample is for RNA expression profiling and must be a fresh biopsy.
  6. of at least 6 months
  7. Female patients of , as defined in Section 5.2.1, must have a negative urine or serum pregnancy test within 72 hours prior to taking the first dose of trial treatment. If the urine test is positive or cannot be confirmed as negative then a serum test is required which must be negative for the patient to enroll. Women of childbearing potential (WOCBP) must be willing to use 2 medically acceptable methods of from Day 1 through 120 days after the last dose of trial treatment. The 2 medically acceptable birth control methods can be either 2 barrier methods or a barrier method plus a hormonal method to prevent pregnancy. The following are considered adequate barrier methods of contraception: diaphragm, condom (by the partner), copper intrauterine device, sponge, or spermicide as per local regulations or guidelines. Appropriate hormonal contraceptives will include any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent (including oral, subcutaneous, intrauterine, or intramuscular agents).

    Male patients of , as described in Section 5.2.1, must agree to use an adequate method of contraception from Day 1 through 120 days after the last dose of trial treatment.

    Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.

    [Inclusion Criteria (Phase 1 only: Melanoma)]

  8. or cytologically confirmed unresectable or metastatic (stage IV) melanoma
  9. For Phase 1 Escalation Cohorts 1-4, must have at least 1 lesion that qualifies as a target lesion per v1.1 except for the minimum measurement of 10 mm in diameter for superficial lesions, is easily accessible (palpable or can be visualized by ultrasound), and is amenable to multiple intratumoral injections. If superficial, the target lesion must be documented photographically.

    [Inclusion Criteria (Phase 2 only: Melanoma)]

  10. Histologically or cytologically confirmed recurrent or unresectable or metastatic (stage IV) melanoma
  11. Must have at least 2 lesions that qualify as a target lesion per RECIST v1.1, and 1 of the qualifying lesions must be easily accessible (palpable or can be visualized by ultrasound) and amenable to multiple intratumoral injections. The target lesion should be of sufficient size such that the required tumor biopsies do not significantly affect tumor assessment per RECIST v1.1. If superficial, the target lesion must measure at least 10 mm in diameter, be measured by calipers, and be documented photographically. Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, are usually not considered measurable unless there has been demonstrated progression in the lesion. Approval from the Medical Monitor is required to inject a previously radiated lesion.
  12. Expansion Cohort 2: Must have documented PD per RECIST v1.1 on a prior treatment regimen containing an anti-PD-1/L1 drug (see Appendix 6 for definition of PD per RECIST v1.1)
  13. Expansion Cohort 8: Must have all of the following:

    1. Received at least 2 doses of an anti-PD-1/L1 therapy
    2. PD occurred within 3 months after last dose of anti-PD-1/L1 therapy
    3. Documented PD per RECIST v.1.1, which has been confirmed by a second assessment at least 4 weeks from the date of the first documented PD, in the absence of rapid clinical progression

    [Inclusion Criteria (Phase 2 only: HNSCC)]

  14. Histologically or cytologically confirmed recurrent or metastatic HNSCC that could not be treated with curative intent
  15. Must have at least 1 lesion that qualifies as a target lesion per RECIST v1.1, and which must be easily accessible (palpable or can be visualized by ultrasound) and amenable to multiple intratumoral injections. The target lesion should be of sufficient size such that the required tumor biopsies do not significantly affect tumor assessment per RECIST v1.1. Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, are usually not considered measurable unless there has been demonstrated progression in the lesion. Approval from the Medical Monitor is required to inject a previously radiated lesion.
  16. Expansion Cohort 4: Must have documented confirmed PD per RECIST v1.1 on a prior treatment regimen containing an anti-PD-1/L1 drug (see Appendix 6 for definition of PD per RECIST v1.1)
  17. Expansion Cohort 7: Must have all of the following:

    1. Received at least 2 doses of an anti-PD-1/L1 therapy, where the last dose of anti-PD-1/L1 therapy was within 6 months of study enrollment (Day 1)
    2. response, ie, PD occurred within 3 months duration of the start of treatment on anti-PD-1/L1 therapy; OR resistant response, ie, PD occurred beyond 3 months duration of treatment on anti-PD-1/L1 therapy and within 6 months after the last dose of treatment on anti-PD-1/L1 therapy
    3. Documented PD per RECIST v.1.1, which has been confirmed by a second assessment at least 4 weeks from the date of the first documented PD, in the absence of rapid clinical progression

[Exclusion Criteria (Phase 1 and Phase 2)]

  1. Received systemic chemotherapy or biological cancer therapy (except anti-PD-1/L1 therapy) within 3 weeks prior to study enrollment
  2. Received prior radiotherapy within 2 weeks of start of study therapy. A shorter may be permitted after approval by the Medical Monitor.
  3. Received small molecule inhibitor targeted therapy, such as tyrosine kinase inhibitors, within 2 weeks prior to study enrollment
  4. Has not recovered to Grade 1 or better from the AEs due to cancer therapeutics prior to study enrollment

    NOTE: Patients with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia or Grade 2 AEs that qualify as Grade 2 due to replacement hormonal or therapy are exceptions to this criterion and may qualify for the study with approval by a Dynavax Medical Monitor.

    If a patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to enrollment.

  5. Received a transfusion of blood products (including platelets or red blood cells) or colony-stimulating factors (including G-CSF, GM-CSF or recombinant erythropoietin) within 4 weeks prior to study enrollment
  6. Is expected to require any other form of anti-cancer therapy while in the trial
  7. Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of therapy (including immune modulators or systemic corticosteroids) within 7 days prior to study enrollment
  8. Positive for active , , or (HIV) infection as determined by laboratory tests for HBsAg, anti-HBc, and anti-HBs; anti-HCV; and anti-HIV -1/2, respectively
  9. History of or current uveal or ocular or mucosal melanoma
  10. Active infection including cytomegalovirus
  11. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial through 120 days after the last dose of trial treatment
  12. Active disease requiring systemic treatment in the past 2 years or a disease that requires immunosuppressive medication including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, or autoimmune thrombocytopenia. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
  13. Current pneumonitis or history of (non-infectious) pneumonitis that required steroids
  14. An immune-related AE from a previous immunotherapeutic agent that has not resolved to Grade 1 or less prior to study enrollment. The exception is a Grade 2 AE which qualifies as Grade 2 due to replacement steroid therapy which may be allowed with approval by a Dynavax Medical Monitor.
  15. Known active central nervous system metastases or carcinomatous meningitis

    NOTE: Patients with previously treated may participate provided they are stable (without evidence of progression by imaging [using the identical imaging modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to the first dose of trial treatment and with any neurologic symptoms returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.

  16. Use of any agent within the last 28 days prior to study enrollment
  17. Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.
  18. Any other significant medical or psychiatric condition, laboratory abnormality, or difficulty complying with protocol requirements that may increase the risk associated with trial participation or trial drug administration that may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for this trial
  19. History of sensitivity to any component of SD-101 or reaction to treatment with a monoclonal antibody and/or any of its
  20. Any known additional that is progressing or requires active treatment. Exceptions are cutaneous melanoma or HNSCC under study per protocol, or basal cell carcinoma of the skin, squamous cell carcinoma of the skin or in situ cervical cancer that has undergone potentially curative therapy.

    [Exclusion Criteria (Phase 2, Melanoma Expansion Cohorts 1 and 5 only)]

  21. Melanoma considered resectable with curative intent
  22. Prior therapy with an anti-PD-1/L1 agent
  23. Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients

    [Exclusion Criteria (Phase 2, Melanoma Expansion Cohorts 2 and 8 only)]

  24. Melanoma considered resectable with curative intent
  25. Any prior combination therapy involving agents given by intratumoral injection that target the innate immune pathway or system such as oncolytic viral or microbial therapy (eg, T-VEC [talimogene laherparepvec]), toll-like receptors (TLR) agonists, STING or RIG-1 and an anti-PD-1/L1 inhibitor

    [Exclusion Criteria (Phase 2, HNSCC Expansion Cohorts 3 and 6 only)]

  26. HNSCC considered resectable with curative intent
  27. Prior therapy with an anti-PD-1/L1 agent
  28. Require anticoagulation therapy

    [Exclusion Criteria (Phase 2, HNSCC Expansion Cohorts 4 and 7 only)]

  29. HNSCC considered resectable with curative intent
  30. Any prior combination therapy involving agents given by intratumoral injection that target the innate immune pathway or system such as oncolytic viral or microbial therapy (eg, T-VEC), TLR agonists, STING or RIG-1 and an anti-PD-1/L1 inhibitor
  31. Require treatment on anticoagulation therapy
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
241 participants (actual)

Study arms

  • Experimental
    Dose Escalation Phase 1b

    Determine the maximum tolerated dose (MTD) of escalating doses of SD-101(1) administered in combination with pembrolizumab in patients with melanoma (anti-PD-1/L1 therapy naïve and experienced patients with progressive disease).

    Drug: SD-101(1) · Biological: Pembrolizumab

  • Experimental
    Dose Expansion Phase 2 (Cohort 1)

    Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.

    Drug: SD-101(2) · Biological: Pembrolizumab

  • Experimental
    Dose Expansion Phase 2 (Cohort 2)

    Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent or metastatic melanoma.

    Drug: SD-101(2) · Biological: Pembrolizumab

  • Experimental
    Dose Expansion Phase 2 (Cohort 3)

    Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.

    Drug: SD-101(2) · Biological: Pembrolizumab

  • Experimental
    Dose Expansion Phase 2 (Cohort 4)

    Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent head and neck squamous cell carcinoma.

    Drug: SD-101(2) · Biological: Pembrolizumab

  • Experimental
    Dose Expansion Phase 2 (Cohort 5)

    Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.

    Biological: SD-101(3) · Biological: Pembrolizumab

  • Experimental
    Dose Expansion Phase 2 (Cohort 6)

    Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.

    Biological: SD-101(3) · Biological: Pembrolizumab

  • Experimental
    Dose Expansion Phase 2 (Cohort 7)

    Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent head and neck squamous cell carcinoma.

    Biological: SD-101(3) · Biological: Pembrolizumab

  • Experimental
    Dose Expansion Phase 2 (Cohort 8)

    Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent or metastatic melanoma.

    Biological: SD-101(3) · Biological: Pembrolizumab

Interventions

  • SD-101 administered intratumorally at escalating doses (up to 11 doses).

  • BiologicalPembrolizumab

    Pembrolizumab administered intravenously, 200 mg Q3W for two years (up to 35 doses).

  • Dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses).

  • BiologicalPembrolizumab

    Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).

  • BiologicalSD-101(3)

    Dose Q1W for 4 weeks followed by dose Q3W for 16 additional weeks (up to 20 total doses).

  • BiologicalPembrolizumab

    Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).

06

What researchers measure

Primary outcomes

  1. Phase 1 Dose Escalation Only - Number of Participants With DLTs

    Dose-limiting toxicities (DLTs) are defined per protocol as specific AEs occurring from the time of the first injection (Day 1) through Day 29.

    Time frame: Day 1 through Day 29

  2. Phase 1 Dose Escalation and Phase 2 Dose Expansion - Overall Response Rate (ORR) by Analysis Group

    Overall response rate (ORR) by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).

    Time frame: Day 1 through Day 743

Secondary outcomes

  1. Phase 1 Dose Escalation and Phase 2 Dose Expansion - Time to Objective Response by Analysis Group

    Time to objective response by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).

    Time frame: Day 1 through Day 743

  2. Phase 1 Dose Escalation and Phase 2 Dose Expansion - Duration of Response by Analysis Group

    Duration of response by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).

    Time frame: Day 1 through Day 743

  3. Phase 1 Dose Escalation and Phase 2 Dose Expansion - Disease Control Rate (DCR) by Analysis Group

    Disease Control Rate (DCR) by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).

    Time frame: Day 1 through Day 743

  4. Phase 1 Dose Escalation and Phase 2 Dose Expansion - Progression-Free Survival Rate by Analysis Group

    Progression-Free Survival (PFS) rate by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).

    Time frame: Day 1 through Day 743

07

Results

Posted Aug 3, 2021
Limitations and caveats
The sponsor terminated the trial early due to strategic restructuring, including the planned conclusion of clinical oncology development programs and no further sponsoring of the development of SD-101.

Participant flow

Phase 1: Dose Escalation
Participant flow — Phase 1: Dose Escalation
MilestoneSD-101 1 mgSD-101 2 mgSD-101 4 mgSD-101 8 mgSD-101 8 mg in Anti-PD-1/L1-Naïve MelanomaSD-101 8 mg in Anti-PD-1/L1-Experienced MelanomaSD-101 8 mg in Anti-PD-1/L1-Naïve HNSCCSD-101 8 mg in Anti-PD-1/L1-Experienced HNSCCSD-101 2 mg in Anti-PD-1/L1-Naïve MelanomaSD-101 2 mg in Anti-PD-1/L1-Naïve HNSCCSD-101 2 mg in Anti-PD-1/L1 Refractory or Resistant HNSCCSD-101 2 mg in Anti-PD-1/L1 Refractory or Resistant Melanoma
Started655600000000
Completed sd-101 treatment (up to 11 doses)330100000000
Completed111000000000
Not completed544600000000
Withdrew: Withdrawal by subject010000000000
Withdrew: Adverse event210000000000
Withdrew: Progressive disease324600000000
Phase 2: Dose Expansion
Participant flow — Phase 2: Dose Expansion
MilestoneSD-101 1 mgSD-101 2 mgSD-101 4 mgSD-101 8 mgSD-101 8 mg in Anti-PD-1/L1-Naïve MelanomaSD-101 8 mg in Anti-PD-1/L1-Experienced MelanomaSD-101 8 mg in Anti-PD-1/L1-Naïve HNSCCSD-101 8 mg in Anti-PD-1/L1-Experienced HNSCCSD-101 2 mg in Anti-PD-1/L1-Naïve MelanomaSD-101 2 mg in Anti-PD-1/L1-Naïve HNSCCSD-101 2 mg in Anti-PD-1/L1 Refractory or Resistant HNSCCSD-101 2 mg in Anti-PD-1/L1 Refractory or Resistant Melanoma
Started0000572523924282330
Completed sd-101 treatment (up to 11 doses)00002573295111
Completed sd-101 treatment cycle 2 (up to 22 doses)000071000000
Completed000050002000
Not completed0000522523922282330
Withdrew: Withdrawal by subject000051101120
Withdrew: Adverse event0000112015010
Withdrew: Progressive disease000022181775171721
Withdrew: Death000011311522
Withdrew: Other00001032010517
Withdrew: Lost to follow-up000010000000
Withdrew: Non-compliance with study drug000020000000

Outcome measures

PrimaryPhase 1 Dose Escalation Only - Number of Participants With DLTs

Dose-limiting toxicities (DLTs) are defined per protocol as specific AEs occurring from the time of the first injection (Day 1) through Day 29.

Time frame:
Day 1 through Day 29
Reported as:
Count of participants · Participants
Phase 1 Dose Escalation Only - Number of Participants With DLTs
ParticipantsSD-101 1 mgSD-101 2 mgSD-101 4 mgSD-101 8 mgSD-101 8 mg in Anti-PD-1/L1-Naïve MelanomaSD-101 8 mg in Anti-PD-1/L1-Experienced MelanomaSD-101 8 mg in Anti-PD-1/L1-Naïve HNSCCSD-101 8 mg in Anti-PD-1/L1-Experienced HNSCCSD-101 2 mg in Anti-PD-1/L1-Naïve MelanomaSD-101 2 mg in Anti-PD-1/L1-Naïve HNSCCSD-101 2 mg in Anti-PD-1/L1 Refractory or Resistant HNSCCSD-101 2 mg in Anti-PD-1/L1 Refractory or Resistant Melanoma
Phase 1 Dose Escalation Only - Number of Participants With DLTs000000000000
PrimaryPhase 1 Dose Escalation and Phase 2 Dose Expansion - Overall Response Rate (ORR) by Analysis Group

Overall response rate (ORR) by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).

Time frame:
Day 1 through Day 743
Reported as:
Count of participants · Participants
Phase 1 Dose Escalation and Phase 2 Dose Expansion - Overall Response Rate (ORR) by Analysis Group
ParticipantsMelanoma Anti-PD-1/L1 Naïve SD-101 2 mgMelanoma Anti-PD-1/L1 Naïve SD-101 8 mgMelanoma Anti-PD-1/L1 Experienced SD-101 2 mgMelanoma Anti-PD-1/L1 Experienced SD-101 8 mgHNSCC Anti-PD-1/L1 Naïve SD-101 2 mgHNSCC Anti-PD-1/L1 Naïve SD-101 8 mgHNSCC Anti-PD-1/L1 Experienced SD-101 2 mgHNSCC Anti-PD-1/L1 Experienced SD-101 8 mg
Complete Response94012001
Partial Response2516734620
Stable Disease28887532
Progressive Disease581211109104
Not Evaluable45475382
SecondaryPhase 1 Dose Escalation and Phase 2 Dose Expansion - Time to Objective Response by Analysis Group

Time to objective response by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).

Time frame:
Day 1 through Day 743
Reported as:
Mean · months
Phase 1 Dose Escalation and Phase 2 Dose Expansion - Time to Objective Response by Analysis Group
monthsMelanoma Anti-PD-1/L1 Naïve SD-101 2 mgMelanoma Anti-PD-1/L1 Naïve SD-101 8 mgMelanoma Anti-PD-1/L1 Experienced SD-101 2 mgMelanoma Anti-PD-1/L1 Experienced SD-101 8 mgHNSCC Anti-PD-1/L1 Naïve SD-101 2 mgHNSCC Anti-PD-1/L1 Naïve SD-101 8 mgHNSCC Anti-PD-1/L1 Experienced SD-101 2 mgHNSCC Anti-PD-1/L1 Experienced SD-101 8 mg
Phase 1 Dose Escalation and Phase 2 Dose Expansion - Time to Objective Response by Analysis Group3.2 ± 1.64.1 ± 2.965.1 ± 3.064.3 ± 2.982.3 ± .922.4 ± 0.872.7 ± 1.092.1 ± 0
SecondaryPhase 1 Dose Escalation and Phase 2 Dose Expansion - Duration of Response by Analysis Group

Duration of response by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).

Time frame:
Day 1 through Day 743
Reported as:
Mean · months
Phase 1 Dose Escalation and Phase 2 Dose Expansion - Duration of Response by Analysis Group
monthsMelanoma Anti-PD-1/L1 Naïve SD-101 2 mgMelanoma Anti-PD-1/L1 Naïve SD-101 8 mgMelanoma Anti-PD-1/L1 Experienced SD-101 2 mgMelanoma Anti-PD-1/L1 Experienced SD-101 8 mgHNSCC Anti-PD-1/L1 Naïve SD-101 2 mgHNSCC Anti-PD-1/L1 Naïve SD-101 8 mgHNSCC Anti-PD-1/L1 Experienced SD-101 2 mgHNSCC Anti-PD-1/L1 Experienced SD-101 8 mg
Phase 1 Dose Escalation and Phase 2 Dose Expansion - Duration of Response by Analysis Group11.1 ± 6.4211.7 ± 5.964.6 ± 6.577.6 ± 7.285.9 ± 4.936.3 ± 3.962.1 ± 0.078.1 ± 0
SecondaryPhase 1 Dose Escalation and Phase 2 Dose Expansion - Disease Control Rate (DCR) by Analysis Group

Disease Control Rate (DCR) by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).

Time frame:
Day 1 through Day 743
Reported as:
Count of participants · Participants
Phase 1 Dose Escalation and Phase 2 Dose Expansion - Disease Control Rate (DCR) by Analysis Group
ParticipantsMelanoma Anti-PD-1/L1 Naïve SD-101 2 mgMelanoma Anti-PD-1/L1 Naïve SD-101 8 mgMelanoma Anti-PD-1/L1 Experienced SD-101 2 mgMelanoma Anti-PD-1/L1 Experienced SD-101 8 mgHNSCC Anti-PD-1/L1 Naïve SD-101 2 mgHNSCC Anti-PD-1/L1 Naïve SD-101 8 mgHNSCC Anti-PD-1/L1 Experienced SD-101 2 mgHNSCC Anti-PD-1/L1 Experienced SD-101 8 mg
Phase 1 Dose Escalation and Phase 2 Dose Expansion - Disease Control Rate (DCR) by Analysis Group36281512131153
SecondaryPhase 1 Dose Escalation and Phase 2 Dose Expansion - Progression-Free Survival Rate by Analysis Group

Progression-Free Survival (PFS) rate by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).

Time frame:
Day 1 through Day 743
Reported as:
Number · percentage of participants
Phase 1 Dose Escalation and Phase 2 Dose Expansion - Progression-Free Survival Rate by Analysis Group
percentage of participantsMelanoma Anti-PD-1/L1 Naïve SD-101 2 mgMelanoma Anti-PD-1/L1 Naïve SD-101 8 mgMelanoma Anti-PD-1/L1 Experienced SD-101 2 mgMelanoma Anti-PD-1/L1 Experienced SD-101 8 mgHNSCC Anti-PD-1/L1 Naïve SD-101 2 mgHNSCC Anti-PD-1/L1 Naïve SD-101 8 mgHNSCC Anti-PD-1/L1 Experienced SD-101 2 mgHNSCC Anti-PD-1/L1 Experienced SD-101 8 mg
3 months85.7 (70.9 to 93.3)71.9 (54 to 83.8)46.7 (28.4 to 63)48 (27.8 to 65.6)46.4 (26.6 to 64.1)43.5 (23.3 to 62.1)31.6 (12.9 to 52.2)37.5 (8.7 to 67.4)
6 months78.4 (62.6 to 88.1)63.3 (45.2 to 76.8)33 (17.2 to 49.8)24 (9.8 to 41.7)26.5 (10.5 to 45.7)17.4 (5.4 to 35)0 (0 to 0)25 (3.7 to 55.8)
9 months70.8 (54.3 to 82.3)60.4 (42.4 to 74.4)21.4 (8.6 to 37.9)14.4 (3.9 to 31.4)21.2 (7.1 to 40.3)17.4 (5.4 to 35)0 (0 to 0)12.5 (0.7 to 42.3)
12 months70.8 (54.3 to 82.3)53.7 (35.7 to 68.7)21.4 (8.6 to 37.9)9.6 (1.7 to 25.7)15.9 (4.2 to 34.4)8.7 (1.5 to 24.2)00 (0 to 0)0 (0 to 0)
15 months65.1 (48.2 to 77.8)49.9 (31.9 to 65.5)0 (0 to 0)9.6 (1.7 to 25.7)15.9 (4.2 to 34.4)4.3 (0.3 to 18.2)00 (0 to 0)0 (0 to 0)
18 months61.5 (44 to 75)40.3 (22.3 to 57.7)0 (0 to 0)9.6 (1.7 to 25.7)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)
21 months61.5 (44 to 75)40.3 (22.3 to 57.7)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)
24 months0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)

Adverse events

Collected over From informed consent through Day 743. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg2/44 (4.5%)15/44 (34.1%)44/44 (100%)
Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg3/39 (7.7%)17/39 (43.6%)39/39 (100%)
Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg5/31 (16.1%)6/31 (19.4%)31/31 (100%)
Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg7/30 (23.3%)9/30 (30%)30/30 (100%)
HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg6/27 (22.2%)8/27 (29.6%)25/27 (92.6%)
HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg13/23 (56.5%)5/23 (21.7%)23/23 (100%)
HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg7/23 (30.4%)10/23 (43.5%)22/23 (95.7%)
HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg3/9 (33.3%)4/9 (44.4%)9/9 (100%)
Most frequent serious events
Showing 10 of 107
Most frequent serious events
EventMelanoma Anti-PD-1/L1 Naïve SD-101 2 mgMelanoma Anti-PD-1/L1 Naïve SD-101 8 mgMelanoma Anti-PD-1/L1 Experienced SD-101 2 mgMelanoma Anti-PD-1/L1 Experienced SD-101 8 mgHNSCC Anti-PD-1/L1 Naïve SD-101 2 mgHNSCC Anti-PD-1/L1 Naïve SD-101 8 mgHNSCC Anti-PD-1/L1 Experienced SD-101 2 mgHNSCC Anti-PD-1/L1 Experienced SD-101 8 mg
Iron deficiency anaemiaBlood and lymphatic system disorders0/440/390/310/300/270/230/231/9
CellulitisInfections and infestations2/440/390/310/301/270/230/231/9
Infected neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/440/390/311/300/270/230/231/9
Ischaemic strokeNervous system disorders0/440/390/310/300/270/230/231/9
Respiratory depressionRespiratory, thoracic and mediastinal disorders0/440/390/310/300/270/230/231/9
Respiratory failureRespiratory, thoracic and mediastinal disorders0/440/390/310/300/270/230/231/9
PneumoniaInfections and infestations0/441/391/313/302/271/231/230/9
MalnutritionMetabolism and nutrition disorders0/440/390/310/301/270/232/230/9
DehydrationMetabolism and nutrition disorders0/443/390/311/301/271/230/230/9
SepsisInfections and infestations2/440/390/310/302/271/231/230/9
Most frequent other events
Showing 10 of 134
Most frequent other events
EventMelanoma Anti-PD-1/L1 Naïve SD-101 2 mgMelanoma Anti-PD-1/L1 Naïve SD-101 8 mgMelanoma Anti-PD-1/L1 Experienced SD-101 2 mgMelanoma Anti-PD-1/L1 Experienced SD-101 8 mgHNSCC Anti-PD-1/L1 Naïve SD-101 2 mgHNSCC Anti-PD-1/L1 Naïve SD-101 8 mgHNSCC Anti-PD-1/L1 Experienced SD-101 2 mgHNSCC Anti-PD-1/L1 Experienced SD-101 8 mg
FatigueGeneral disorders33/4431/3913/3122/3015/2717/237/235/9
HeadacheNervous system disorders23/4425/399/3114/303/2710/232/234/9
ChillsGeneral disorders19/4420/396/3116/303/2710/232/231/9
MyalgiaMusculoskeletal and connective tissue disorders18/4417/392/3116/301/279/231/232/9
MalaiseGeneral disorders14/4420/394/3111/300/270/232/232/9
DiarrhoeaGastrointestinal disorders21/4411/396/317/302/277/230/230/9
PyrexiaGeneral disorders10/4415/397/317/306/276/236/234/9
Injection site erythemaGeneral disorders17/449/394/3113/301/274/232/231/9
NauseaGastrointestinal disorders13/4415/399/3110/308/278/230/230/9
ArthralgiaMusculoskeletal and connective tissue disorders16/448/393/314/300/270/230/230/9

Baseline characteristics

The intent-to-treat (ITT) population comprises all participants who received at least one dose of SD-101. Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101, as specified by the statistical analysis plan. Participants who received 1 mg or 4 mg of SD-101 in Phase 1: Dose Escalation of the study are not included in the analysis groups.

Age, Categorical
Age, Categorical(Participants)Melanoma Anti-PD-1/L1 Naïve SD-101 2 mgMelanoma Anti-PD-1/L1 Naïve SD-101 8 mgMelanoma Anti-PD-1/L1 Experienced SD-101 2 mgMelanoma Anti-PD-1/L1 Experienced SD-101 8 mgHNSCC Anti-PD-1/L1 Naïve SD-101 2 mgHNSCC Anti-PD-1/L1 Naïve SD-101 8 mgHNSCC Anti-PD-1/L1 Experienced SD-101 2 mgHNSCC Anti-PD-1/L1 Experienced SD-101 8 mgTotal
<=18 years000000000
Between 18 and 65 years161813171610154109
>=65 years29231813121385121
Age, Continuous
Age, Continuous(years)Melanoma Anti-PD-1/L1 Naïve SD-101 2 mgMelanoma Anti-PD-1/L1 Naïve SD-101 8 mgMelanoma Anti-PD-1/L1 Experienced SD-101 2 mgMelanoma Anti-PD-1/L1 Experienced SD-101 8 mgHNSCC Anti-PD-1/L1 Naïve SD-101 2 mgHNSCC Anti-PD-1/L1 Naïve SD-101 8 mgHNSCC Anti-PD-1/L1 Experienced SD-101 2 mgHNSCC Anti-PD-1/L1 Experienced SD-101 8 mgTotal
Mean66.2 ± 13.3465.3 ± 12.4465.6 ± 12.9962.4 ± 15.2562.6 ± 10.6667.2 ± 9.5961.0 ± 12.9465.2 ± 12.3564.4 ± 12.45
Sex: Female, Male
Sex: Female, Male(Participants)Melanoma Anti-PD-1/L1 Naïve SD-101 2 mgMelanoma Anti-PD-1/L1 Naïve SD-101 8 mgMelanoma Anti-PD-1/L1 Experienced SD-101 2 mgMelanoma Anti-PD-1/L1 Experienced SD-101 8 mgHNSCC Anti-PD-1/L1 Naïve SD-101 2 mgHNSCC Anti-PD-1/L1 Naïve SD-101 8 mgHNSCC Anti-PD-1/L1 Experienced SD-101 2 mgHNSCC Anti-PD-1/L1 Experienced SD-101 8 mgTotal
Female1314107928164
Male322721231921158166
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Melanoma Anti-PD-1/L1 Naïve SD-101 2 mgMelanoma Anti-PD-1/L1 Naïve SD-101 8 mgMelanoma Anti-PD-1/L1 Experienced SD-101 2 mgMelanoma Anti-PD-1/L1 Experienced SD-101 8 mgHNSCC Anti-PD-1/L1 Naïve SD-101 2 mgHNSCC Anti-PD-1/L1 Naïve SD-101 8 mgHNSCC Anti-PD-1/L1 Experienced SD-101 2 mgHNSCC Anti-PD-1/L1 Experienced SD-101 8 mgTotal
Hispanic or Latino0214002110
Not Hispanic or Latino433728262822208212
Unknown or Not Reported222001108
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Melanoma Anti-PD-1/L1 Naïve SD-101 2 mgMelanoma Anti-PD-1/L1 Naïve SD-101 8 mgMelanoma Anti-PD-1/L1 Experienced SD-101 2 mgMelanoma Anti-PD-1/L1 Experienced SD-101 8 mgHNSCC Anti-PD-1/L1 Naïve SD-101 2 mgHNSCC Anti-PD-1/L1 Naïve SD-101 8 mgHNSCC Anti-PD-1/L1 Experienced SD-101 2 mgHNSCC Anti-PD-1/L1 Experienced SD-101 8 mgTotal
White444130252420199212
Black or African American100002205
Asian001121207
Other000420006
ECOG Performance Status
ECOG Performance Status(Participants)Melanoma Anti-PD-1/L1 Naïve SD-101 2 mgMelanoma Anti-PD-1/L1 Naïve SD-101 8 mgMelanoma Anti-PD-1/L1 Experienced SD-101 2 mgMelanoma Anti-PD-1/L1 Experienced SD-101 8 mgHNSCC Anti-PD-1/L1 Naïve SD-101 2 mgHNSCC Anti-PD-1/L1 Naïve SD-101 8 mgHNSCC Anti-PD-1/L1 Experienced SD-101 2 mgHNSCC Anti-PD-1/L1 Experienced SD-101 8 mgTotal
0283019165642110
1171112142317197120
PDL1 Expression
PDL1 Expression(Participants)Melanoma Anti-PD-1/L1 Naïve SD-101 2 mgMelanoma Anti-PD-1/L1 Naïve SD-101 8 mgMelanoma Anti-PD-1/L1 Experienced SD-101 2 mgMelanoma Anti-PD-1/L1 Experienced SD-101 8 mgHNSCC Anti-PD-1/L1 Naïve SD-101 2 mgHNSCC Anti-PD-1/L1 Naïve SD-101 8 mgHNSCC Anti-PD-1/L1 Experienced SD-101 2 mgHNSCC Anti-PD-1/L1 Experienced SD-101 8 mgTotal
Positive211391314154796
Negative1415811245160
Unknown101314612414174
08

Study locations

47 sites
  • University of Alabama School of Medicine
    Birmingham, Alabama 35294, United States
  • University of Alabama
    Birmingham, Alabama 35294, United States
  • University of Arizona Cancer Center
    Tucson, Arizona 85721, United States
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
  • Stanford Hospitals and Clinics
    Palo Alto, California 94305, United States
  • University of California, San Diego
    San Diego, California 92093, United States
  • University of California San Francisco
    San Francisco, California 94158, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Mount Sinai Comprehensive Cancer Center
    Miami Beach, Florida 33140, United States
  • Georgia Cancer Center - Northside Hospital Central Research Department
    Atlanta, Georgia 30341, United States
  • Northwestern University
    Chicago, Illinois 60208, United States
  • University of Iowa Healthcare
    Iowa City, Iowa 52242, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • University of Minnesota Masonic Cancer Center
    Minneapolis, Minnesota 55455, United States
  • Nebraska Methodist Hospital
    Omaha, Nebraska 68130, United States
  • Atlantic Health
    Morristown, New Jersey 07962, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • The Christ Hospital
    Cincinnati, Ohio 45219, United States
  • University Hospitals Cleveland Medical Center - Seidman Cancer center
    Cleveland, Ohio 44106, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Mary Crowley Cancer Research Center
    Dallas, Texas 75230, United States
  • University of Utah Health Care - Huntsman Cancer institute
    Salt Lake City, Utah 84112, United States
  • Inova Schar Cancer Institute
    Fairfax, Virginia 22031, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
  • The Tweed Hospital
    Tweed Heads, New South Wales 2485, Australia
  • Liverpool Hospital
    Westmead, New South Wales 2170, Australia
  • Melanoma Institute
    Wollstonecraft, New South Wales 2065, Australia
  • Adelaide Cancer Centre - Ashford Cancer Centre
    Kurralta Park, South Australia 5037, Australia
  • Hollywood Private Hospital / Affinity Research
    Nedlands, Western Australia, Australia
  • Charité - Universitätsmedizin Berlin
    Berlin, Germany
  • Klinikum BuxtehudeDermato-Onkologie Studienzentrale
    Buxtehude, Germany
  • Uniklinikum Dresden Klinik und Poliklinik für Dermatologie
    Dresden, Germany
  • Universitätshautklinik Frankfurt
    Frankfurt, Germany
  • Medizinische Hochschule Hannover
    Hannover, Germany
  • HNO-Universitätsklinik Jena
    Jena, Germany
  • Universitätshautklinik Magdeburg
    Magdeburg, Germany
  • Universitätsklinikum Regensburg
    Regensburg, Germany
  • Universitätsklinikum Tübingen
    Tubingen, Germany
  • Auckland City Hospital
    Auckland, 1023, New Zealand
  • Christchurch Hospital
    Christchurch, 4710, New Zealand
  • Waikato Hospital
    Hamilton, 3204, New Zealand
09

References and documents

Publications

  • Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. Cancer Discov. 2018 Oct;8(10):1250-1257. doi: 10.1158/2159-8290.CD-18-0280. Epub 2018 Aug 28. PubMed 30154193 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data will be shared under guidance of the New Rule - FDAAA 801 eff. Jan 2017. 3/2017 - additional changes forthcoming.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Apr 2020 and a completion of Apr 2020. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2021, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2015
First posted
Aug 13, 2015
Start
Sep 2015
Primary completionActual
Apr 2020
CompletionActual
Apr 2020
Results first posted
Aug 3, 2021
Last update
Aug 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02521870
Responsible party
Sponsor
First posted
Aug 13, 2015
Start date
Sep 2015
Primary completion
Apr 2020
Completion
Apr 2020
Results posted
Aug 3, 2021
Last update
Aug 3, 2021

Study contacts

Antoni Ribas, MD
principal investigator · UCLA School of Medicine (Melanoma)
Ezra Cohen, MD
principal investigator · UCSD Moores Cancer Center (HNSCC)
Thomas Tüting, MD
principal investigator · University Hospital Magdeburg

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nelitolimod

Start the discussion